Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 188-195 , May 2007

Kidney cancer: Past, present, and future

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–1631
  3. Cohen HT, McGovern FJ. Renal cell carcinoma. NEJM. 2005;353:2477–2490
  4. Campbell SC, Novick AC, Bukowski RM. Renal tumors. In:  Wein AJ,  Kavoussi LR,  Novick AC, et al. editor. Campbell-Walsh Urology. 3rd ed.. Philadelphia (PA): Saunders/Elsevier; 2007;p. 1567–1637
  5. Kim WY, Kaelin WG. The role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004
  6. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumors. J Pathol. 1997;183:131–133
  7. Lane BR, Rini BI, Novick AC, et al. Targeted molecular therapy for renal cell carcinoma. Urology. 2007;69:3–10
  8. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: The SSIGN score. J Urol. 2002;168:2395–2400
  9. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51
  10. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–1657
  11. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464–5471
  12. Lane B, Kattan M, Novick AC. Prediction models of renal cell carcinoma (AUA Update Series). Vol 25. 2006;Lesson 7
  13. Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol. 2006;175:425–431
  14. Permpongkosol S, Chan DY, Link RE, et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol. 2005;174:1222–1225
  15. Hollenbeck BK, Taub DA, Miller DC, et al. National utilization trends of partial nephrectomy for renal cell carcinoma: A case of underutilization?. Urology. 2006;67:254–259
  16. Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med. 2002;53:393–407
  17. Leibovich BC, Blute ML, Cheville JC, et al. Nephron-sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171:1066–1070
  18. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181–2185
  19. Mitchell RE, Gilbert SM, Murphy AM, et al. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67:260–264
  20. Campbell SC, Novick AC. Expanding the indications for elective partial nephrectomy: Is this advisable?. Eur Urol. 2006;49:952–954
  21. Clark P, Schover L, Uzzo R, et al. Quality of life and psychological adaptation following surgical treatment for localized renal cell carcinoma: Impact of the amount of remaining renal tissue. Urology. 2001;57:252–256
  22. Novick AC, Gephardt G, Guz B, et al. Long-term follow-up after partial removal of a solitary kidney. NEJM. 1991;10:1058–1062
  23. Novick AC, Schreiber MJ. The effect of angiotensin converting enzyme inhibition on nephropathy in patients with a remnant kidney. Urology. 1995;46:785–789
  24. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236–1242
  25. McKienan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–820
  26. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumors: A retrospective cohort study. Lancet Oncol. 2006;7:735–740
  27. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron-sparing surgery for localized renal cell carcinoma: 10-year follow-up. J Urol. 2000;163:442–444
  28. Fergany AF, Saad IR, Woo L, et al. Open partial nephrectomy for tumor in a solitary kidney: Experience with 400 cases. J Urol. 2006;175:1630–1633
  29. Gill I, Matin S, Desai M, et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol. 2003;170:64–68
  30. Hegarty NJ, Gill IS, Desai MM, et al. Probe-ablative nephron-sparing surgery: Cryoablation vs. radiofrequency ablation. Urol. 2006;68(Suppl 1):7–13
  31. Hegarty N, Gill I, Kaouk JH, et al. Renal cryoablation: 5-year outcomes. J Urol. 2006;175:351
  32. Illing R, Leslie TA, Kennedy JE, et al. High-intensity focused ultrasound for the treatment of small renal tumors: The Oxford experience. J Urol. 2006;175:236–237
  33. Kohrmann KU, Michael MS, Gaa J, et al. High intensity focused ultrasound as noninvasive therapy for multifocal renal cell carcinoma: Case study and review of the literature. J Urol. 2002;167:2397–2403
  34. Ponsky LE, Novick AC, Crownover R, et al. The initial evaluation of cyberknife technology for extracorporeal renal tissue ablation. Urology. 2003;61:498–501
  35. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell, renal-cell carcinoma. NEJM. 2007;356:125–134
  36. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  37. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:4508
  38. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. NEJM. 2007;356:115–124
  39. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006;24(Suppl I):217s
  40. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434

PII: S1078-1439(07)00075-0

doi: 10.1016/j.urolonc.2007.03.006

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 188-195 , May 2007

Article Tools

* Image Usage & Resolution